Affiliate Disclosure
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →
Educational Notice
This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on acetyl tetrapeptide-3. It is not medical advice, a treatment recommendation, or a substitute for professional consultation. Hair loss has multiple causes requiring individual assessment. Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
A Comprehensive Evidence Review — Follicle ECM Anchoring, Capixyl® Data, and the Procapil® Comparison
Acetyl tetrapeptide-3 is the second ECM-anchoring peptide in the Hair & Follicle cluster, and it has an interesting competitive history with its near-sibling biotinoyl tripeptide-1. Both target follicle basement membrane reinforcement. Both entered the market as the peptide component of a three-ingredient commercial complex — biotinoyl tripeptide-1 in Procapil® (Sederma/Croda), acetyl tetrapeptide-3 in Capixyl® (Lucas Meyer/IFF). Both have small manufacturer-sponsored human combination studies. And crucially, Capixyl® published a direct comparison against Procapil® — making this one of the few cases in the cosmetic peptide world where two proprietary actives have been formally compared head-to-head, however imperfectly.
Acetyl tetrapeptide-3’s mechanism overlaps with biotinoyl tripeptide-1 — both upregulate laminin-5 and reinforce the follicular basement membrane — but with differences in peptide sequence, combination partner chemistry, and cellular emphasis. Where biotinoyl tripeptide-1 uses the GHK tripeptide sequence with a biotin conjugation and pairs with plant-derived DHT inhibitors, acetyl tetrapeptide-3 uses an acetylated tetrapeptide sequence and pairs with biochanin A, a red clover-derived isoflavone with selective estrogen receptor modulating and 5α-reductase inhibitory properties. The combination strategies are similar in intent — address both hormonal signaling and structural ECM deterioration — but the specific components differ.
This article covers acetyl tetrapeptide-3’s mechanism, the Capixyl® evidence base, the head-to-head Procapil® comparison, and what honest assessment of the available data looks like for each delivery route.
Quick Facts
INCI Name
Acetyl Tetrapeptide-3
Mechanism Class
ECM signal peptide — upregulates laminin-5 and additional basement membrane proteins to reinforce follicle anchorage
Evidence Tier
Pilot Data — combination study (Capixyl®) with human outcomes; Procapil® head-to-head comparison published
Commercial Context
Active peptide component of Capixyl® (Lucas Meyer/IFF) — combined with biochanin A (red clover extract)
Regulatory Status
Cosmetic ingredient. Not FDA approved as a drug.
WADA Status
Not prohibited
Capixyl® Comparison Result
Capixyl® reported superior to Procapil® in manufacturer comparison study — 12% vs. 9% hair density improvement
Key Comparator
Biotinoyl tripeptide-1 / Procapil® — direct head-to-head published by Lucas Meyer; similar ECM mechanism
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Acetyl Tetrapeptide-3?
Acetyl tetrapeptide-3 is a synthetic acetylated tetrapeptide developed as the active peptide component of Capixyl® by Lucas Meyer Cosmetics (now part of IFF — International Flavors & Fragrances). Its mechanism targets the follicular extracellular matrix — specifically the laminin and collagen IV components of the basement membrane that anchor hair follicles to the surrounding dermis. The acetyl modification at the N-terminus improves the peptide’s lipophilicity and resistance to aminopeptidase degradation, extending its effective half-life in formulation and at the target tissue.
The compound’s cellular targets are the same as biotinoyl tripeptide-1 — outer root sheath keratinocytes and follicle dermal papilla cells — but the receptor interactions and downstream gene expression changes documented in Lucas Meyer’s technical studies differ in emphasis. Where biotinoyl tripeptide-1 focuses primarily on laminin-5 (LAMA3, LAMB3, LAMC2) and collagen IV, Capixyl® technical documentation reports upregulation of a broader ECM protein set including fibronectin, collagen VII, and laminin β1 alongside laminin-5 and collagen IV. Whether this broader ECM profile translates to meaningfully different clinical outcomes is unknown — the head-to-head comparison data shows a modest advantage for Capixyl® but cannot determine whether the peptide component or the biochanin A partner is responsible.
Origins and Development
Capixyl® was developed by Lucas Meyer Cosmetics in direct response to Procapil®’s success in the cosmetic hair care market. The strategic design was similar: combine a peptide with ECM-anchoring activity with a plant-derived DHT-addressing active into a single commercial complex. Lucas Meyer selected biochanin A — an isoflavone from red clover (Trifolium pratense) — as the DHT-addressing component rather than Procapil®’s apigenin and oleanolic acid. Biochanin A is a phytoestrogen with published 5α-reductase type II inhibitory activity, the same enzyme target as finasteride, which provides a mechanistic basis for the DHT-addressing half of the combination.
The acetyl tetrapeptide-3 component was designed to complement biochanin A’s hormonal mechanism with ECM structural reinforcement — the same rationale as Procapil®’s biotinoyl tripeptide-1. Lucas Meyer published the Capixyl® clinical data in product documentation and then notably included a direct head-to-head comparison against Procapil® — an unusual move in the cosmetic ingredient industry, where direct competitor comparisons are rare. The comparison showed Capixyl® superior on the reported endpoints, though the methodology is subject to the same limitations as all manufacturer-sponsored cosmetic ingredient studies.
Mechanism of Action
Acetyl tetrapeptide-3 activates dermal papilla cells and follicle outer root sheath keratinocytes through ECM receptor-mediated signaling, producing upregulation of basement membrane structural proteins including laminin-5, collagen IV, fibronectin, and collagen VII. This broader ECM protein profile addresses multiple components of the follicle’s structural anchor system simultaneously. Laminin-5 reinforcement strengthens hemidesmosomal adhesion (the primary bond between outer root sheath cells and the basement membrane). Fibronectin and collagen VII contribute to the anchoring fibril system that attaches the basement membrane to the underlying dermis. Together these reinforce the complete follicle anchoring architecture rather than a single component of it.
In Capixyl®, the biochanin A component addresses the upstream DHT-mediated Wnt suppression and follicle miniaturization signaling, while acetyl tetrapeptide-3 addresses the downstream structural consequence — the loss of ECM anchorage in miniaturizing follicles. This two-pronged approach mirrors Procapil®’s design logic: address both the hormonal signal and the structural damage it produces.
Plain English
Hair follicles are anchored in place by a web of structural proteins — think of it as the scaffolding that holds each follicle in the dermis. In pattern hair loss that scaffolding degrades. Acetyl tetrapeptide-3 tells the cells that build this scaffolding to produce more of it, targeting several scaffold proteins simultaneously rather than just one. Whether enough of the peptide reaches those cells through the scalp to make a real difference in living humans is the question the in vitro data cannot answer.
Capixyl®: The Combination Context
Capixyl® is a two-ingredient complex combining acetyl tetrapeptide-3 (ECM-anchoring peptide) and biochanin A (red clover isoflavone, 5α-reductase type II inhibitor). Lucas Meyer’s proprietary studies for Capixyl® include in vitro demonstrations of the ECM protein upregulation mechanism and a human clinical study in male AGA patients.
The primary published Capixyl® human study enrolled men with AGA and applied a 3% Capixyl® formulation twice daily for 4 months. The reported outcomes included improvement in hair density (approximately 12% increase from baseline in the primary endpoint group) and reduction in hair loss rate. These figures are from Lucas Meyer’s own documentation, not from an independently published peer-reviewed journal article. The same attribution limitation applies as for Procapil® — acetyl tetrapeptide-3’s individual contribution to the combination’s results cannot be isolated.
Evidence context: Capixyl® clinical data is Lucas Meyer manufacturer-sponsored. The study design mirrors Procapil®’s approach: small sample, twice-daily topical application, 4-month duration, hair count and density endpoints. The head-to-head comparison with Procapil® was also conducted and reported by Lucas Meyer — not by an independent academic group. Both the standalone Capixyl® data and the comparison data are subject to manufacturer bias and cannot be considered independently confirmed.
Acetyl Tetrapeptide-3 vs. Biotinoyl Tripeptide-1: What the Comparison Data Shows
Lucas Meyer published a direct head-to-head comparison of Capixyl® versus Procapil® — an unusually aggressive competitive positioning that deserves careful examination. In the reported comparison, both formulations were applied at their recommended concentrations (3%) twice daily for 4 months in male AGA patients. Capixyl® produced approximately 12% improvement in hair density versus Procapil®’s approximately 9% — a modest but consistent advantage across the reported endpoints.
| Capixyl® (Acetyl Tetrapeptide-3 + Biochanin A) | Procapil® (Biotinoyl Tripeptide-1 + Apigenin + Oleanolic Acid) | |
|---|---|---|
| Peptide component | Acetyl tetrapeptide-3 — broader ECM protein profile (laminin-5, collagen IV, fibronectin, collagen VII) | Biotinoyl tripeptide-1 (Biotin-GHK) — primarily laminin-5 and collagen IV; biotin cofactor delivery |
| DHT-addressing component | Biochanin A — red clover isoflavone; 5α-reductase type II inhibitor | Apigenin + oleanolic acid — chamomile flavonoid and olive/rosemary triterpene; anti-androgenic activity |
| Reported hair density improvement (4 months) | ~12% from baseline (Lucas Meyer data) | ~9% from baseline (Sederma data — different study context) |
| Head-to-head comparison | Lucas Meyer-sponsored — Capixyl® favored | Sederma never published a reverse comparison |
| Independent replication | None published | None published |
| Cost | Typically higher per gram — proprietary IFF/Lucas Meyer ingredient | Typically lower per gram — Croda/Sederma with generic alternatives available |
The honest read of the comparison: Capixyl® probably works at least as well as Procapil® based on mechanistically similar approaches with slightly different chemistry, and the manufacturer comparison favors Capixyl® by a modest margin. But a comparison conducted by the company that makes one of the two products being compared is not independent evidence. The 12% vs. 9% figures cannot be taken as definitive given the source. For practical formulation decisions, the two are mechanistically interchangeable enough that cost and supplier relationships often determine the choice — and using both at reduced individual concentrations is a defensible approach that avoids the manufacturer-bias problem by not requiring a winner.
Key Research and Studies
In Vitro ECM Studies
Lucas Meyer’s technical documentation for Capixyl® includes in vitro studies showing acetyl tetrapeptide-3 upregulates laminin-5, collagen IV, fibronectin, and collagen VII in human follicle outer root sheath cells and dermal papilla cell cultures. The broader ECM protein profile distinguishes Capixyl® from Procapil® in manufacturer documentation. These studies confirm the cellular mechanism operates at relevant peptide concentrations in culture. They do not address scalp penetration or in vivo follicle tissue concentrations.
Biochanin A 5α-Reductase Research
Biochanin A’s 5α-reductase type II inhibitory activity has been characterized in independent published research separate from Lucas Meyer’s Capixyl® program. A study by Hirata et al. (2004) demonstrated that biochanin A inhibits 5α-reductase type II at IC50 values relevant to topical application, providing independent validation of the DHT-addressing component that is separate from manufacturer claims. This independent research on biochanin A is meaningfully different from relying entirely on manufacturer characterization — the active DHT half of Capixyl® has a better independent evidence base than most cosmetic ingredient combinations.
Capixyl® Human Clinical Study
Lucas Meyer’s primary Capixyl® human study enrolled male AGA patients applying 3% Capixyl® solution twice daily for 4 months. Primary endpoints included phototrichogram-measured hair density and hair loss rate. The reported 12% improvement in hair density and reduction in hair loss rate represents the primary human outcome evidence for this compound. The study is manufacturer-sponsored, small, and not independently replicated. The same framework as Procapil® applies: the results are real from the study, cannot be attributed specifically to the peptide component, and represent pilot data rather than clinical trial evidence.
Common Claims versus Current Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Clinically proven to reduce hair loss” | Capixyl® combination shows ~12% hair density improvement and reduced hair loss in manufacturer study. Small, industry-sponsored, not independently replicated. Acetyl tetrapeptide-3’s individual contribution unknown. | Combination pilot data; standalone contribution unquantified |
| “Better than Procapil®” | Lucas Meyer’s own comparison study favored Capixyl®. This comparison was conducted by the maker of Capixyl®. The result should be treated as manufacturer marketing supported by internal data, not as independent validation. | Manufacturer comparison favors Capixyl®; independent confirmation absent |
| “Works like a natural DHT blocker” | Biochanin A has published independent 5α-reductase type II inhibitory activity. At topical cosmetic concentrations, the DHT-blocking effect is present but weaker than pharmaceutical finasteride. “Natural DHT blocker” is accurate in mechanism but overstates clinical potency. | Mechanism accurate; clinical potency overstated |
| “Suitable for all hair loss types” | Evidence is in AGA. ECM anchoring addresses AGA-specific basement membrane degradation. Alopecia areata, telogen effluvium, and scarring alopecia have different pathophysiology. | AGA evidence only — other types unstudied |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
The Human Evidence Landscape
Acetyl tetrapeptide-3 sits in essentially the same evidence position as biotinoyl tripeptide-1: pilot data from combination studies, no standalone clinical trial, manufacturer-sponsored, not independently replicated. The difference is that Capixyl® has one additional piece of data — the head-to-head comparison with Procapil® — which biotinoyl tripeptide-1 lacks. That comparison adds some information about relative performance, even if the information comes with obvious bias caveats.
The biochanin A component’s independent 5α-reductase evidence is a genuine differentiator for the Capixyl® combination versus Procapil®. Apigenin and oleanolic acid also have anti-androgenic activity characterized in published literature, but biochanin A’s 5α-reductase type II inhibitory data is more specifically targeted to the relevant enzyme. This means the DHT-addressing half of Capixyl® may have a somewhat stronger mechanistic foundation than Procapil®’s anti-androgenic components — though this does not determine which combination product produces better clinical outcomes, which remains unknown from independent data.
Safety, Risks, and Limitations
Acetyl tetrapeptide-3 has a favorable safety profile consistent with other cosmetic tetrapeptides. The acetyl modification does not introduce known toxicological concerns. Contact sensitization is not a reported issue. No systemic adverse events have been attributed to topical use. Biochanin A, as a phytoestrogen, carries theoretical hormonal activity concerns at high systemic doses, but at topical cosmetic concentrations the systemic absorption is insufficient to produce meaningful estrogenic or antiandrogenic systemic effects. The safety profile of both components is acceptable for topical cosmetic use.
For scalp microneedling applications, the standard sterility requirements apply. Bacteriostatic water for injection is the appropriate reconstitution medium. Cosmetic-grade acetyl tetrapeptide-3 is not manufactured to pharmaceutical sterility standards, and introducing it through open microneedling channels bypasses the stratum corneum barrier protection.
Legal and Regulatory Status
Acetyl tetrapeptide-3 is a cosmetic ingredient regulated under standard US and EU cosmetic frameworks. No FDA pre-market approval required. Capixyl® is a registered trademark of IFF/Lucas Meyer Cosmetics; generic acetyl tetrapeptide-3 is available from multiple suppliers. WADA: not prohibited.
Formulation and Protocol Considerations
Concentration: The Capixyl® combination study used 3% of the two-ingredient complex. Supplier recommendations for standalone acetyl tetrapeptide-3 suggest 1–4% in finished formulations. As with Procapil®, the acetyl tetrapeptide-3 concentration within the Capixyl® complex is not publicly specified.
Using both ECM peptides: Combining acetyl tetrapeptide-3 and biotinoyl tripeptide-1 in a single formulation is a reasonable approach that avoids the manufacturer-comparison problem. The two peptides target the same mechanism (ECM anchoring) but with different sequences and potentially different ECM protein emphases. Whether the combination produces additive ECM benefit beyond either compound alone is unknown, but the mechanism is non-competing and the cost of including both at reduced concentrations (1–2% each) is modest. This is a more intellectually honest approach than picking a winner from manufacturer data.
Full multi-mechanism stack: PTD-DBM (Wnt activation) + acetyl tetrapeptide-3 and/or biotinoyl tripeptide-1 (ECM anchoring) + minoxidil (perfusion) covers the major independent AGA mechanisms. Adding a pharmaceutical 5α-reductase inhibitor (finasteride or dutasteride) upstream addresses the DHT-mediated signaling that biochanin A addresses less potently at topical concentrations.
Dosing and Delivery: What the Research Shows
Topical Application
The evidence-based protocol mirrors the Capixyl® study: 3% concentration in a leave-on aqueous solution, twice daily to affected scalp areas, minimum 4 months. The acetyl modification improves lipophilicity relative to unmodified tetrapeptides, providing some penetration advantage through the stratum corneum’s lipid phase. The target cells (follicle outer root sheath keratinocytes) are at dermal depth, and topical delivery is challenged by the same stratum corneum and viable epidermis barriers as all other scalp peptides. The peripilar follicular route may contribute to scalp peptide absorption beyond passive transdermal diffusion.
Scalp Microneedling / Stamping
Scalp microneedling at 0.5–1.0 mm followed by acetyl tetrapeptide-3 solution application is the primary enhanced delivery approach in the self-experimentation community. The target cells (outer root sheath keratinocytes at follicle depth) are directly accessible at these needle depths — a better target-depth match than NMJ-targeting facial peptides. No published trial for this specific combination. Bacteriostatic water for injection as reconstitution medium is essential for microneedling applications.
Scalp Mesotherapy
Professional intradermal scalp injection delivers the peptide directly to the dermis adjacent to follicle outer root sheath cells — the most efficient route to the target tissue. No published trial for mesotherapy-delivered acetyl tetrapeptide-3. In the professional mesotherapy context with pharmaceutical-grade or aseptically prepared materials, this represents the most mechanistically direct delivery route.
Delivery Routes in Self-Experimentation Communities
| Route | Community Use | Evidence | Key Risks |
|---|---|---|---|
| Topical serum / Capixyl® product | Common — both commercial Capixyl® products and standalone peptide in DIY serums; often combined with biotinoyl tripeptide-1 | Capixyl® combination pilot data; biochanin A independent 5α-RII data; in vitro ECM mechanism confirmed | Low — favorable safety profile; source quality varies |
| Scalp microneedling + topical | Widely practiced alongside PTD-DBM, biotinoyl tripeptide-1, and minoxidil in comprehensive hair loss protocols | No specific trial; good target depth match for ORS cells; mechanistically coherent | Moderate — scalp sterility; bacteriostatic water required; temporary post-procedure shedding normal |
| Scalp mesotherapy (professional) | Medical procedure context; not at-home | No specific published trial; strong delivery rationale; established procedure for hair loss | Low in professional context with proper sterile technique |
In community practice, acetyl tetrapeptide-3 and biotinoyl tripeptide-1 are often used together rather than as alternatives. The “both ECM peptides together” approach is practical, cost-effective, and sidesteps the manufacturer-comparison problem by treating them as complementary rather than competing. The most commonly reported protocol in evidence-focused hair loss communities combines PTD-DBM + acetyl tetrapeptide-3 + biotinoyl tripeptide-1 + minoxidil, often with scalp microneedling, representing a genuine multi-mechanism approach across Wnt activation, ECM anchoring, and vascular/follicle perfusion.
Frequently Asked Questions
Q1: What is acetyl tetrapeptide-3 and how does it work for hair loss?
A1: Acetyl tetrapeptide-3 is the active peptide component of Capixyl® (IFF/Lucas Meyer). It works by upregulating the structural proteins that form the follicle’s basement membrane — particularly laminin-5, collagen IV, fibronectin, and collagen VII. These proteins anchor each hair follicle to the surrounding dermis. In androgenetic alopecia, this anchoring system progressively degrades as follicles miniaturize, making them easier to shed and harder to maintain in the growth phase. Acetyl tetrapeptide-3 addresses this structural deterioration, working at the ECM level rather than through hormonal or growth signaling pathways.
Q2: Is Capixyl® better than Procapil®?
A2: Lucas Meyer published a head-to-head comparison showing Capixyl® produced ~12% hair density improvement versus ~9% for Procapil® at 4 months. However, this comparison was conducted by Lucas Meyer — the company that makes Capixyl®. A manufacturer reporting that their own product outperforms the competitor’s product is not the same as independent validation. Both products work through similar ECM-anchoring mechanisms with different peptide sequences and different DHT-addressing plant extracts. The honest answer is: the comparison is informative but biased, and the most rational approach is to use both together at moderate concentrations rather than picking a winner from manufacturer data.
Q3: What is biochanin A and why is it in Capixyl®?
A3: Biochanin A is an isoflavone from red clover (Trifolium pratense) with published independent evidence of 5α-reductase type II inhibitory activity — the same enzyme that converts testosterone to DHT in scalp dermal papilla cells. This is the same enzyme that finasteride inhibits, making biochanin A a weaker but mechanistically relevant natural alternative. Its inclusion in Capixyl® addresses the hormonal component of AGA while acetyl tetrapeptide-3 addresses the resulting structural ECM deterioration. Biochanin A’s independent 5α-reductase data is a genuine differentiator for Capixyl® versus Procapil®’s apigenin and oleanolic acid combination.
Q4: Can I use both acetyl tetrapeptide-3 and biotinoyl tripeptide-1 together?
A4: Yes — and in many ways this is the better approach than choosing between them. Both target ECM anchoring through different peptide sequences and potentially different emphases in the ECM protein profile they upregulate. Using both at 1–2% each instead of one at 3% gives you mechanistic coverage across a broader ECM protein set without relying on manufacturer comparisons to pick a winner. The cost of including both is modest, the mechanisms are non-competing, and you sidestep the manufacturer-bias problem entirely. This is standard practice in the most evidence-focused hair loss self-experimentation communities.
Q5: How does acetyl tetrapeptide-3 fit into a comprehensive AGA protocol?
A5: As the ECM-anchoring component. The most mechanistically coherent AGA protocol addresses multiple independent biological targets: PTD-DBM activates the Wnt/β-catenin pathway (the growth signal suppressed by DHT), acetyl tetrapeptide-3 and biotinoyl tripeptide-1 reinforce the ECM structural anchor (the physical deterioration caused by miniaturization), minoxidil improves follicle perfusion and extends anagen, and a pharmaceutical 5α-reductase inhibitor (finasteride or dutasteride) addresses DHT production upstream. These four intervention points are mechanistically independent — no molecular competition, potentially additive effects.
Q6: Can acetyl tetrapeptide-3 be used with scalp microneedling?
A6: Yes. The follicle outer root sheath cells that respond to acetyl tetrapeptide-3’s ECM signaling are located at dermal depths directly accessible by 0.5–1.0 mm scalp microneedling channels. This makes the target-to-depth match for scalp microneedling with this compound better than for facial NMJ-targeting peptides whose targets are below typical needle depth. No published trial exists for this combination. Bacteriostatic water for injection is the required reconstitution medium — cosmetic-grade peptide materials are not manufactured to pharmaceutical sterility standards, and microneedling bypasses the skin’s natural barrier protection.
Q7: Is acetyl tetrapeptide-3 safe?
A7: Yes — the safety profile is excellent. No significant adverse events have been reported with topical use. Biochanin A at topical cosmetic concentrations does not produce meaningful systemic estrogenic effects despite being a phytoestrogen — the systemic absorption from scalp application is insufficient. The compound is well-tolerated across scalp types. The standard sterility considerations apply for microneedling applications.
Related Compounds: How Acetyl Tetrapeptide-3 Compares
Acetyl tetrapeptide-3’s closest comparison is biotinoyl tripeptide-1 — both are ECM-anchoring peptides targeting follicle basement membrane reinforcement, with similar combination-study evidence and no standalone clinical trials. The comparison table below shows all compounds in the Hair & Follicle cluster across mechanism, evidence tier, and delivery route data.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Hair Growth Mechanism | Route / Application | Human Hair Evidence | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Biotinoyl Tripeptide-1 (Biotinylated GHK, Hair-Growth Targeting Copper Peptide) | Synthetic tripeptide conjugated to biotin (Biotin-Gly-His-Lys, biotin-modified GHK) | Hair follicle growth factor signaling (FGF / IGF-1 pathway proposed); copper-dependent metalloproteases | ~1–2 hours (topical) | Not FDA-approved (cosmetic / nutraceutical ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen extension; hair shaft strengthening (biotin carrier adds structural support) | Topical (shampoos, conditioners, scalp serums); Oral supplement (biotin component) | Limited human hair studies. Primarily marketed in hair-care cosmetics with anecdotal reports | Biotin-conjugated GHK targeting hair follicles specifically. Dual mechanism: copper peptide + biotin nutritional support |
| KGF / Palifermin (Keratinocyte Growth Factor) | Recombinant human FGF-7 (189-amino-acid heparin-binding growth factor) | FGF7R / HSPG (heparan sulfate proteoglycan); hair follicle epithelial growth | ~2–3 hours (injection); ~1 hour (topical — if penetrant) | FDA-approved (Kepivance for oral mucositis in hematologic malignancy patients) | Prohibited — S2 (Growth factor) | Tier 1 — Approved Drug (for mucositis indication; hair growth off-label) | Hair follicle keratinocyte proliferation (FGF-7 signaling); hair shaft diameter enlargement; hair cycle modulation (anagen phase extension proposed) | Subcutaneous or intradermal injection (research); Topical formulations under development | FDA-approved for oral mucositis (2004). Hair-growth studies limited; mostly preclinical or cosmetic-industry data | FGF-7 is gold-standard growth factor for hair follicle epithelium. Approved drug repurposed for hair (off-label interest) |
| Thymulin (Zinc-Thymulin) | Synthetic nonapeptide-zinc complex (Ac-SDAEPQ, zinc-dependent immuno-peptide from thymic epithelium) | Thymic T-cell development; hair follicle immune tolerance (proposed) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Thymic peptide hormone / growth factor) | Tier 4 — Preclinical Only | Hair follicle immune homeostasis (Th1/Th2 balance restoration); hair loss prevention via immune-mediated follicle protection (proposed) | Subcutaneous injection or topical (research formulations) | Zero human hair-loss studies published. Theoretical application based on immune function support | Thymic zinc peptide with general immune function. Proposed hair-loss mechanism via immune tolerance (alopecia areata context) |
| Substance P | Endogenous undecapeptide (11-amino-acid neuropeptide: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) | Tachykinin receptor 1 (NK1R) signaling; neuroinflammation and hair follicle support | ~1–2 minutes (blood serum); ~30 minutes (tissue microenvironment) | Not FDA-approved (endogenous neuropeptide, investigational) | Not WADA-listed (endogenous neuropeptide at physiologic levels) | Tier 4 — Preclinical Only | Neurogenic inflammation modulation (NK1R activation); hair follicle innervation support; anagen phase promotion (proposed in stress-induced alopecia contexts) | Subcutaneous or intradermal injection (research); Topical (experimental formulations) | Minimal human hair studies. Mostly rodent stress-alopecia models | Endogenous neuropeptide with rapid serum degradation. Proposed alopecia treatment via stress-pathway modulation |
| Copper Peptides: GHK-Cu & AHK-Cu | Two synthetic tripeptide-copper complexes (Gly-His-Lys + Cu²⁺ vs. Ala-His-Lys + Cu²⁺) | Collagen / Elastin synthesis; FGF signaling; hair follicle dermal papilla support | ~1–2 hours (topical) | Not FDA-approved (topical cosmetic ingredients widely used) | GHK-Cu: Prohibited — S0 (injectable); AHK-Cu: Not WADA-listed (topical) | GHK-Cu: Tier 5 — It’s Complicated | AHK-Cu: Tier 4 — Preclinical Only | Hair follicle collagen remodeling and stem cell support (GHK-Cu: broad effects; AHK-Cu: follicle-specific) | Topical only (shampoos, conditioners, serums; injectable GHK-Cu rare/unstandardized) | Topical: 30+ years cosmetic use (GHK-Cu more extensive); AHK-Cu: limited comparative studies | GHK-Cu: broader cosmetic/systemic research; AHK-Cu: more stable in formulations, follicle-targeted variant |
| IGF-1 (Insulin-Like Growth Factor 1, Recombinant) | Recombinant human 70-amino-acid growth factor peptide | IGF-1R (Type 1 insulin-like growth factor receptor); hair follicle stem cell proliferation | ~4–8 hours (injection); ~30 minutes (serum half-life) | Not FDA-approved for hair loss (approved for growth hormone deficiency pediatric indication only — Increlex) | Prohibited — S2 (Growth factor, IGF-1 analog) | Tier 2 — Clinical Trials (Phase II in hair loss) — historical | Hair follicle proliferation (IGF-1R signaling); anagen phase extension; hair shaft diameter increase (proposed) | Subcutaneous injection (research formulations); Topical (experimental — poor dermal penetration) | Phase II trials in alopecia (1990s—early 2000s); limited publication. Off-label interest in androgenetic alopecia | Recombinant growth factor with potent follicle effects in vitro/vivo. Systemic effects and cost limit practical use |
| Acetyl Tetrapeptide-3 (Hair-Growth Peptide) | Synthetic tetrapeptide (Ac-Glu-Glu-Lys-Ser, acetylated quadrapeptide) | Hair follicle growth factor signaling (proposed; exact mechanism unclear) | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen phase support; hair loss prevention (claims in cosmetic formulations) | Topical (shampoos, conditioners, scalp treatments) | Anecdotal cosmetic-industry reports only. No peer-reviewed human hair-loss studies | Short synthetic peptide with proprietary mechanism. Limited published evidence vs. marketing |
| PTD-DBM (Protein Transduction Domain — Double Binding Motif) | Synthetic peptide construct combining protein transduction domain (PTD) with collagen-binding domains (DBM) | Dermal collagen remodeling; hair follicle dermal papilla matrix support (proposed) | ~2–3 hours (topical/dermal penetration) | Not FDA-approved (research/cosmetic ingredient in development) | Not WADA-listed (topical research peptide) | Tier 4 — Preclinical Only | Hair follicle dermal matrix remodeling; collagen cross-linking enhancement (proposed) | Topical (serums, scalp treatments); potentially transdermal via PTD moiety | Limited studies. Primarily research-phase formulations | Combines transduction and collagen-binding domains for enhanced dermal penetration and matrix remodeling |
Summary and Key Takeaways
Acetyl tetrapeptide-3 and biotinoyl tripeptide-1 occupy the same evidence tier and the same mechanistic niche — ECM-anchoring peptides for the follicle basement membrane. The distinction is in the peptide sequence (acetylated tetrapeptide vs. biotin-GHK), the combination partner (biochanin A vs. apigenin/oleanolic acid), and the manufacturer (IFF/Lucas Meyer vs. Croda/Sederma). The Capixyl® vs. Procapil® head-to-head is a legitimate data point but comes from the interested party. The biochanin A 5α-reductase II data adds independent mechanistic support for the DHT-addressing component that is somewhat stronger than Procapil®’s equivalent. For practical use: both together at moderate concentrations is a better approach than choosing between them on the basis of manufacturer comparisons.
- Acetyl tetrapeptide-3 is the ECM-anchoring peptide component of Capixyl® (IFF/Lucas Meyer), targeting laminin-5, collagen IV, fibronectin, and collagen VII upregulation in follicle outer root sheath cells to reinforce the basement membrane anchorage system degraded in AGA.
- Evidence tier: pilot data (combination). Capixyl® combination study reported ~12% hair density improvement at 4 months; Lucas Meyer head-to-head comparison favors Capixyl® over Procapil® by ~3 percentage points. Both data sources are manufacturer-associated.
- Biochanin A, Capixyl®’s DHT-addressing component, has independently published 5α-reductase type II inhibitory activity — a stronger independent foundation for the combination’s anti-androgenic half than relying solely on manufacturer characterization.
- Mechanism is non-competing with PTD-DBM (Wnt activation), minoxidil (vasodilation), and pharmaceutical DHT inhibitors. The full multi-mechanism AGA stack — PTD-DBM + acetyl tetrapeptide-3/biotinoyl tripeptide-1 + minoxidil ± finasteride — covers independent biological targets with no molecular overlap.
- Combining acetyl tetrapeptide-3 and biotinoyl tripeptide-1 together at 1–2% each is a more intellectually honest approach than choosing a winner from manufacturer comparison data.
- Safety: excellent profile for both components. Biochanin A phytoestrogenic activity is not significant at topical cosmetic concentrations. No systemic adverse events reported.
- Scalp microneedling is well-motivated — follicle ORS cells at dermal depth are accessible at 0.5–1.0 mm channel depth. BWI reconstitution required.
- WADA: not prohibited. Capixyl® is a registered trademark of IFF/Lucas Meyer. Generic acetyl tetrapeptide-3 available from multiple suppliers.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References and Key Studies
- Lucas Meyer Cosmetics / IFF technical documentation: Capixyl® active ingredient dossier. Available at: lucasmeyercosmetics.com
- Hirata N, et al. Inhibitory activity of isoflavones on testosterone 5α-reductase. Chem Pharm Bull. 2004;52(3):378–80. PMID 14993803 — independent biochanin A 5α-reductase type II inhibition data
- Mori T, et al. Cyclic stretch of the scalp skin with hair traction evokes follicle distortion resulting in hair shedding. J Dermatol Sci. 2005. — follicle ECM anchoring biology context
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94. PMID 14996087 — ECM and follicle biology context
Further Reading
- Hair & Follicle Research Cluster — Peptidings.com
- Biotinoyl Tripeptide-1: Research Overview — Peptidings.com — the companion ECM-anchoring peptide; Procapil® vs. Capixyl® comparison context
- PTD-DBM: Research Overview — Peptidings.com — Wnt activator with the strongest standalone clinical evidence in the cluster
- Copper Peptides for Hair: GHK-Cu vs AHK-Cu — Peptidings.com
- Peptide Microneedling & Stamping Guide — Peptidings.com
- PubMed: Biochanin A 5α-Reductase Research
- Evidence Levels Explained — Peptidings.com
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing here should be interpreted as a recommendation to use any compound for hair loss treatment.
Acetyl tetrapeptide-3 is a cosmetic ingredient, not an FDA-approved drug. Published human data is available only for the Capixyl® two-ingredient combination; acetyl tetrapeptide-3’s individual contribution cannot be isolated from that data. Capixyl® is a registered trademark of IFF/Lucas Meyer Cosmetics.
Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
← Previous
Next →
Resources & Further Research
Where to Go From Here
The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.
Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →
Telehealth Options
Happy Head
A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.
View Treatment Options →All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.